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BACKGROUND: Data about high-grade glioma (HGG) in very young 
children (≤3  years old at diagnosis) is scarce.  METHODS: 180 pedi-
atric HGG patients were treated at the Children Cancer Hospital - Egypt 
(CCHE-57357) between July 2007 and June 2018, with 17 patients aged 
≤3  years at diagnosis. Medical records were retrospectively reviewed for 
clinical, radiological and histopathological data, treatment received and 
survival outcome. RESULTS: Median age was 29.2 months (range: 2.4 – 
35.8 months; males = 9). Most frequent pathological diagnosis was Glio-
blastoma, WHO grade-IV (n = 11, 64.7%) and one patient had H3-mutant 
diffuse midline glioma. All patients underwent surgery (gross-total resec-
tion, n = 6, 35.3%; subtotal-resection, n = 5, 29.4%; biopsy, n = 6, 35.3%). 
One patient (age = 7 months) progressed and died before starting adjuvant 
therapy. All patients ≤1 year of age (n = 5) received adjuvant chemotherapy 
(CT) only, older children (n  =  11) received adjuvant radiotherapy (RT) 
(total dose range: 54 – 60 Gy) and CT (CCG-945 protocol). The 1-year 
overall survival (OS) rate was 47.1%; and event-free survival (EFS) rate 
was 35.3%. EFS differed between those who received RT and those who 
did not (1-year EFS 54.5% and 0% respectively, p = 0.001). Compared to 
older children, anatomical distribution of tumors was significantly different 
with non-midline locations being the commonest in patients ≤3 years old 
(88.2% vs 46.4%, p=0.01).  CONCLUSIONS: HGG in very young chil-
dren arise predominantly in non-midline locations and usually lack the 
H3-mutation. RT seems crucial in the management of pHGG regardless 
of age subgroup.
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ONC201, a bitopic DRD2 antagonist and allosteric ClpP agonist, has 
shown encouraging efficacy in H3 K27M-mutant glioma. Given that the 
thalamus has the highest extra-striatal expression of DRD2, we performed 
an integrated preclinical and clinical analysis of ONC201 in thalamic H3 
K27M-mutant glioma. ONC201 was effective in mouse intra-uterine elec-
troporation (IUE)-generated H3 K27M-mutant gliomas, with an in vitro 
IC50 of 500 nM and 50% prolongation of median survival in vivo (p=0.02, 
n=14). We analyzed thalamic H3 K27M-mutant glioma patients treated with 
ONC201 on active clinical trials as of 5/22/19 enrollment (n=19 recurrent 
and 10 post-radiation, non-recurrent; 5–70 years old). As of 12/18/2019, 
PFS6 and OS12 are 26.3% and 36.8%, respectively, in the recurrent group. 
For non-recurrent patients, with median follow up of 21.9  months (8.6–
26.6) from diagnosis, median PFS or OS have not been reached. This sur-
passes historical OS of 13.5 months. Best response by RANO includes 1 
CR, 3 PR, 4 SD, 8 PD for recurrent patients and 2 PR, 4 SD, 1 PD for non-
recurrent patients (4 on-trial patients experienced regressions that are yet 
unconfirmed responses). Median duration of response for recurrent patients 
is 14.0 months (2.0–33.1). Furthermore, H3 K27M cell-free tumor DNA in 
plasma and CSF correlated with MRI response. In summary, single agent 
ONC201 administered at recurrence, or adjuvantly following radiation, 
demonstrates promising clinical efficacy in thalamic H3 K27M-mutant 
glioma patients who currently have no effective treatments following ra-
diation. Investigations are ongoing to assess whether micro-environmental 
DRD2 expression explains the early exceptional responses in thalamic H3 
K27M-mutant glioma.
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Pediatric high-grade gliomas (pHGG) are heterogeneous brain tumors 
for which new specific diagnostic/prognostic biomarkers are needed. In this 
study, we aimed to identify new pHGG subgroup specific biomarkers by 
exploiting exosomes, known vehicles of oncogenic signals. We used plasma 
from 23 patients (including 6 controls) and conditioned medium from 12 
patient-derived cell-lines, representing all locational and molecular sub-
groups. Upon exosome isolation, total RNA was extracted and miRNAs 
were assessed using a PCR Panel. Analysis of plasma miRNome showed 
that tumor exosomal samples were largely clustered together, independently 
from their locational and/or molecular subgroup. We identified 20 signifi-
cantly upregulated and 25 downregulated miRNAs compared to controls. 
Interestingly, 27 miRNAs were expressed only in tumors. Furthermore, 
the unsupervised clustering showed a clear separation based on locational 
(hemispheric vs pontine) and mutational (WT vs H3.3G34R or H3.3G34R 
vs H3K27M) subgroup comparisons, with the identification of distinct 
miRNomes underlying the key role of location and mutations in defining the 
pHGG exosomal miRNA profile. This was further confirmed analyzing the 
miRNOme from cell-line derived exosomes. Moreover, we identified a pool 
of significantly differentially regulated miRNAs in diagnose vs relapse and 
biopsy vs autopsy cell-lines. Most importantly, when comparing hemispheric 
vs pontine and H3.3G34R vs H3.3K27M, we identified respectively four 
and three miRNas equally dysregulated and in common between plasma 
and cell-lines. Those were strongly associated mainly to transcriptional regu-
lation and targeting TTC9, linked to cancer invasion and metastasis. Based 
on this, we suggest exosomal miRNAs as a powerful new pHGG diagnostic/
prognostic tool.
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